# v4.30

## Related releases

## Data changes

### Gene

```
ASCL1 Background Updated
ASCL1 Summary Updated
ATMIN Background Updated
ATMIN Summary Updated
DLL3 Background Updated
DLL3 Summary Updated
```

### Alteration

```
ASCL1 Amplification, Mutation Effect, Description Updated
ASCL1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ASCL1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ASCL1 Amplification Added
ASCL1 IGH-ASCL1 Fusion, Mutation Effect, Description Updated
ASCL1 IGH-ASCL1 Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ASCL1 IGH-ASCL1 Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ASCL1 IGH-ASCL1 Fusion Added
ATMIN Deletion, Mutation Effect, Description Updated
ATMIN Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
ATMIN Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ATMIN Deletion Added
ATMIN Truncating Mutations, Mutation Effect, Description Updated
ATMIN Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
ATMIN Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ATMIN Truncating Mutations Added
BRCA2 P564L, Mutation Effect, Description Updated
BRCA2 P564L, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA2 P564L, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA2 P564L Added
CAMTA1 Truncating Mutations, Mutation Effect, Description Updated
CAMTA1 Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CAMTA1 Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CAMTA1 Truncating Mutations Added
JAK2 505_547del [Exon 12 in-frame deletions], Mutation Effect, Description Updated
LTK CLIP1-LTK Fusion Name Changed
	 New: CLIP1-LTK Fusion
	 Old: CLIP1-LTK fusion
NOTCH1 1_2250trunc [Truncating mutations upstream of transactivation domain] (upstream of transactivation domain), Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Yes
NOTCH1 1_2250trunc [Truncating mutations upstream of transactivation domain] (upstream of transactivation domain), Mutation Effect, Description Updated
NPM1 Deletion, Mutation Effect, Description Updated
NPM1 W288fs, Mutation Effect, Description Updated
NPM1 Truncating Mutations, Mutation Effect, Description Updated
TP53 R290C, Mutation Effect, Description Updated
TP53 R290C, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
TP53 R290C, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
TP53 R290C Added
```

### Evidence

```
ASCL1 Gene Type, Oncogene Updated
ATMIN Gene Type, Tumor Suppressor Updated
DLL3 Gene Type, Oncogene Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Description Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Summary Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Zongertinib, Description Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Zongertinib, FDA Level Updated
	 New: Fda3
	 Old: no
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Zongertinib, Level Updated
	 New: 3A
	 Old:
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Zongertinib, Propagation to Other Liquid Tumor Types Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Zongertinib, Propagation to Other Solid Tumor Types Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Zongertinib 3A Added
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Sevabertinib, Description Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Sevabertinib, FDA Level Updated
	 New: Fda3
	 Old: no
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Sevabertinib, Level Updated
	 New: 3A
	 Old:
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Sevabertinib, Propagation to Other Liquid Tumor Types Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Sevabertinib, Propagation to Other Solid Tumor Types Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Sevabertinib 3A Added
ERBB2 Oncogenic Mutations, Other Tumor Types, Summary Updated
JAK2 Oncogenic Mutations, Polycythemia Vera, Summary Updated
JAK2 Oncogenic Mutations, Chronic Neutrophilic Leukemia, Summary Updated
JAK2 Fusions, Leukemia Deleted
JAK2 Oncogenic Mutations, All Tumors Deleted
JAK2 Oncogenic Mutations, Myeloproliferative Neoplasms, Summary Updated
JAK2 Oncogenic Mutations, Essential Thrombocythemia, Summary Updated
JAK2 Oncogenic Mutations, Primary Myelofibrosis, Summary Updated
JAK2 Oncogenic Mutations, Essential Thrombocythemia Myelofibrosis, Polycythaemia Vera Myelofibrosis, Summary Updated
NRG1 Fusions, All Solid Tumors, Zenocutuzumab, Description Updated
NRG1 Fusions, Non-Small Cell Lung Cancer, Zenocutuzumab, Description Updated
NRG1 Fusions, Pancreatic Adenocarcinoma, Zenocutuzumab, Description Updated
ROS1 Fusions, Other Tumor Types, Summary Updated
ROS1 Fusions, Non-Small Cell Lung Cancer, Summary Updated
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib, Description Updated
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib, FDA Level Updated
	 New: Fda2
	 Old: Fda3
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib, Level Updated
	 New: 1
	 Old: 3A
ROS1 Oncogenic Mutations, All Tumors, Summary Updated
```
